Moderna, Inc.
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 5/30567% above fair value
$220.83−0.89 (-0.40%)
Close on Nov 2, 2026Market cap $88.16BP/E –Yield –
Moderna Discovery programs R&D by Year
Discovery programs R&D (FY2018–FY2023 disaggregation) ($M) ($M)
Moderna Discovery programs R&D: $106M in FY2023, up 53.6% from a year earlier. No newer figure appears in the documents we track.
Latest, FY2023
106
Period ended Dec 31, 2023
Change on a year earlier
+53.6%
69 in FY2022
History
6 years
Since FY2018
Sources
3
Documents cited below
Where the FY2023 figure comes from
“Discovery programs | $ | 106 | $ | 69 | $ | 85”
Source: FY2023 10-K ↗
Reported in Form 10-K / 10-Q Item 7 (MD&A R&D Breakdown).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Discovery programs R&D (FY2018–FY2023 disaggregation) ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2023 | Dec 31, 2023 | 106 | +53.6% | FY2023 10-K ↗ |
| FY2022 | Dec 31, 2022 | 69 | -18.8% | FY2023 10-K ↗ |
| FY2021 | Dec 31, 2021 | 85 | +51.8% | FY2023 10-K ↗ |
| FY2020 | Dec 31, 2020 | 56 | 0.0% | FY2021 10-K ↗ |
| FY2019 | Dec 31, 2019 | 56 | +61.6% | FY2021 10-K ↗ |
| FY2018 | Dec 31, 2018 | 34.6 | – | FY2020 10-K ↗ |
Cite this data
StockData. (2026). Moderna Discovery programs R&D ($M), annual FY2018–FY2023 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/rd-discovery-programs-leg
See every metric in the Moderna KPI table. Data updated Nov 3, 2026.